FindTrial
Sign In

gemcitabine/nab-paclitaxel

DRUG7 trials

Sponsors

Eli Lilly and Company, Nathan Bahary, MD, Massachusetts General Hospital, Duke University, University Health Network, Toronto

Conditions

Advanced Pancreatic CancerBorderline Resectable Pancreatic CancerBreast CancerColorectal CancerColorectal CarcinomaHead and Neck CancerLung CancerMTAP Deletion

Phase 1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
CompletedNCT02009449
Eli Lilly and CompanyBreast Cancer, Colorectal Carcinoma, Melanoma +6
Start: 2013-11-15End: 2023-07-22Updated: 2024-11-15
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
CompletedNCT04666688
PureTechColorectal Cancer, Head and Neck Cancer, Metastatic Cancer +3
Start: 2020-12-15End: 2024-12-12Updated: 2025-02-12
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
RecruitingNCT06922591
Tango Therapeutics, Inc.Lung Cancer, MTAP Deletion, NSCLC +5
Start: 2025-05-31End: 2027-12-31Target: 183Updated: 2025-12-11

Phase 2

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
TerminatedNCT02241551
Nathan Bahary, MDBorderline Resectable Pancreatic Cancer
Start: 2014-12-31End: 2017-03-03Updated: 2018-07-26
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
TerminatedNCT02243007
Massachusetts General HospitalPancreatic Ductal Carcinoma, Resectable Pancreatic Cancer
Start: 2014-09-30End: 2016-06-30Updated: 2017-05-16
Pancreatic Adenocarcinoma Signature Stratification for Treatment
CompletedNCT04469556
University Health Network, TorontoAdvanced Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma
Start: 2020-10-14End: 2025-03-05Updated: 2026-02-20

Unknown Phase

Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
CompletedNCT02318095
Duke UniversityResectable Pancreatic Cancers
Start: 2015-02-17End: 2022-11-14Updated: 2023-10-26

Related Papers

Abstract B086: External validation of a multimodal machine learning system to predict outcomes in advanced pancreatic cancer in the PASS-01 trial
Cancer Research2025-09-28
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.
2024-08-0121 citations
Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.
Journal of Clinical Oncology2024-06-0517 citations
Abstract C063: Keratin 17 as a predictor of chemotherapy response in pancreatic ductal adenocarcinoma
Cancer Research2024-01-16
128P A phase I dose escalation and expansion trial of LYT-200: A galectin-9 antibody +/- tislelizumab
Immuno-Oncology Technology2023-12-012 citations
hENT1 as a Predictive Biomarker in PDAC—Response
Clinical Cancer Research2023-08-013 citations
Lyt-200, a Humanized Anti-Galectin-9 Antibody, Exhibits Preclinical Efficacy in Models of Hematological Malignancies
Blood2022-11-156 citations
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Nature Communications2022-08-26116 citations
PASS-01: Pancreatic adenocarcinoma signature stratification for treatment–01.
Journal of Clinical Oncology2022-01-1917 citations
482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors
Regular and Young Investigator Award Abstracts2021-11-0110 citations
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Cancer Research2020-11-131 citations
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
Investigational New Drugs2020-09-1014 citations
Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).
Journal of Clinical Oncology2020-05-202 citations
Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).
Journal of Clinical Oncology2020-05-201 citations
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study.
Journal of Clinical Oncology2020-02-191 citations
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
2019-09-25100 citations
Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors
Annals of Oncology2018-10-013 citations
Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy
Annals of Oncology2018-10-012 citations
Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)
Annals of Oncology2018-10-011 citations
Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors
Annals of Oncology2018-10-01

19 more papers not shown